Darmiyan
$10Mtotal raised · 2 rounds on record
$3.5Mlatest round · Venture round · Oct 2023 · 3 yr ago
4backers · Y Combinator, Pegasus Tech Ventures
10+team · employees, estimated range
Overview
About us. We are a team of neuroscientists, data scientists, healthcare experts and patient advocates focused on improving the lives of millions of people around the world who suffer from brain diseases.
Funding and backers
Total raised
$10M
2 rounds on record
Latest round
$3.5M
Venture round · Oct 2023 · 3 yr ago
Team
11-50
employees, estimated range
Backers
4
Y Combinator, Pegasus Tech Ventures
The money's age
Long since its last round
37 months since the last round · not hiring
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Sep 16, 2024
Launched Darmiyan, Inc. Announces Launch Of Groundbreaking Brainsee Platform For Alzheimer's Testing · menafn.com
Jan 12, 2024
Certified Darmiyan Receives FDA Approval for BrainSee, the First Prognostic Test for Predicting Likelihood of Progression to Alzheimer's Dementia · streetinsider.com
Oct 10, 2023
Raised a round Venture round $3.5M · SEC Form D
Mar 31, 2020
Raised a round Venture round $6.4M · SEC Form D
Jun 2017
Went through Y Combinator
2016
Founded
Tractionpublic signals, read monthly
Web presence
top 6%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Oct 2023 | $3.5M | — | SEC Form D |
| Venture round | Mar 2020 | $6.4M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Darmiyan, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Padideh Kamali-ZareExecutive OfficerSEC Form D
Kaveh VejdaniDirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Don't deal with your health alone. Get paired with a dedicated patient advocate to help you navigate healthcare needs. Covered by Medicare.
Our mission is to improve the lives of the millions that suffer from food allergies and gluten-related disorders.
_able is making meaningful financial access simple and within reach - for hundreds of millions of people.
Over two billion women globally suffer from uterine diseases that impact the endometrium. We’re here to change that.
CVAUSA empowers cardiovascular specialists to transform patient care. Our MSO healthcare experts provide the technology & support you need…
Our Mission. Deliver medicines that transform the lives of patients with neurodegenerative diseases.
People
Padideh Kamali-Zare
Executive Officer
Kaveh Vejdani
Director
Shirai Takehiro
Director
Takehiro Shirai
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
UpHonest CapitalVia a fund
Pegasus Tech VenturesVia a fund
Soma CapitalVia a fund
876 portfolio companies
Y CombinatorVia a fund
6310 portfolio companies
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Letter Of Intent With Darmiyan, Inc. To Explore Use Of FDA De Novo Authorized Brainsee(R) AI Platform In ...
Read more
Report
California Association of Health Facilities (CAHF) Selects Darmiyan as Preferred Provider for Cognitive Health Solutions
The California Association of Health Facilities (CAHF) has selected Darmiyan, Inc., a leading neurotechnology company, as its only Preferred Provider for Cognitive Health Solutions. Through this partnership, more than 1,300 CAHF member facilities, serving
Read more
Report
Darmiyan Receives FDA Approval for Post-Market Surveillance Study of BrainSee, the First-in-Class Clinical Test for Predicting Risk of Progression to Clinical Alzheimer
Darmiyan, Inc., a leading brain health technology company, today announced that the U.S. Food and Drug Administration (FDA) has approved the company
Read more
Report
Darmiyan Receives FDA Approval for Post-Market Surveillance Study of BrainSee, the First-in-Class Clinical Test for Predicting Risk of Progression to Clinical Alzheimer
/PRNewswire/ -- Darmiyan, Inc., a leading brain health technology company, today announced that the U.S. Food and Drug Administration (FDA) has approved the...
Read more
Report
Darmiyan, Inc. Announces Launch Of Groundbreaking Brainsee Platform For Alzheimer's Testing
Read more
Report
MCRA Supports Darmiyan with FDA Approval for BrainSee Device
/PRNewswire/ -- MCRA, the leading privately held independent medical device, diagnostics, and biologics Clinical Research Organization (CRO) and advisory firm...
Read more
Report
Imvaria and Darmiyan receive FDA authorizations for AI-enabled diagnostic tools
The de novo classifications cover software for detecting a lung condition and assessing dementia risk.
Read more
Report
Darmiyan获得FDA对BrainSee的批准这是首个能够预测阿尔茨海默病痴呆症发展可能性的预后测试
美国食品药物管理局 (FDA) 对 BrainSee 的 De Novo 批准代表了在阿尔兹海默症诊断上的重大进步BrainSee 采用了先进的图像处理技术并由医学人工智能提供支持为从遗忘型轻度认知障碍 (aMCI)...
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
San Francisco
United States
HQ
10-50 est. staff